The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
Introduction <br/> Helminth infection may affect vaccine immunogenicity and efficacy. Adolescents, a target population for tuberculosis booster vaccines, often have a high helminth burden. We investigated effects of Schistosoma mansoni (Sm) on the immunogenicity and safety of MVA85A, a model c...
Autores principales: | Wajja, A, Kizito, D, Nassanga, B, Nalwoga, A, Kabagenyi, J, Kimuda, S, Galiwango, R, Mutonyi, G, Vermaak, S, Satti, I, Verweij, J, Tukahebwa, E, Cose, S, Levin, J, Kaleebu, P, Elliott, A, McShane, H |
---|---|
Otros Autores: | Diemert, D |
Formato: | Journal article |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Ejemplares similares
-
The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
por: Anne Wajja, et al.
Publicado: (2017-05-01) -
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A
por: Wajja, A, et al.
Publicado: (2018) -
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
por: Wajja, A, et al.
Publicado: (2024) -
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A [version 1; referees: 1 approved, 2 approved with reservations]
por: Anne Wajja, et al.
Publicado: (2018-09-01) -
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial
por: Wajja, A, et al.
Publicado: (2023)